All Releases
 |
Sangamo BioSciences Reports Second Quarter 2010 Financial Results
Jul 28, 2010
|
17.3 KB |
|
| |
RICHMOND, Calif., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported second quarter 2010 financial results and accomplishments.
For the second quarter ended June 30, 2010, Sangamo reported a consolidated net loss of $3.9 million, or $0.09 per share, compared to a net loss of $4.5 million, ...
|
|
Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
Jul 21, 2010
|
7.6 KB |
|
| |
RICHMOND, Calif., July 21, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second quarter 2010 financial results on Wednesday, July 28, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to ...
|
|
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Jul 6, 2010
|
13.4 KB |
|
| |
RICHMOND, Calif., July 6, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ZFN appro...
|
|
Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinson's Disease
Jul 1, 2010
|
10.7 KB |
|
| |
RICHMOND, Calif., July 1, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has been awarded a second round of funding by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support studies in non-human primates for the development of a ZFP Therapeutic(TM) to treat Parkinson's...
|
|
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data From SB-509 Programs in Diabetic Neuropathy at ADA 2010
Jun 29, 2010
|
19.3 KB |
|
| |
RICHMOND, Calif., June 29, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA), held in Orlan...
|
|
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Jun 3, 2010
|
7.4 KB |
|
| |
RICHMOND, Calif., June 3, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, and Ward Wolff, executive vice president and CFO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the compa...
|
|
Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
May 24, 2010
|
10.4 KB |
|
| |
RICHMOND, Calif., May 24, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein (ZFP) Therapeutics(TM) were described in fifteen presentations given by Sangamo scientists and collaborators at...
|
|
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
May 4, 2010
|
7.4 KB |
|
| |
RICHMOND, Calif., May 4, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at two investor conferences ...
|
|
Sangamo BioSciences Reports First Quarter 2010 Financial Results
May 3, 2010
|
15.1 KB |
|
| |
RICHMOND, Calif., May 3, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2010 financial results and accomplishments.
For the first quarter ended March 31, 2010, Sangamo reported a consolidated net loss of $4.0 million, or $0.09 per share, compared to a net loss of $6.8 million, or ...
|
|
Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast
Apr 26, 2010
|
7.6 KB |
|
| |
RICHMOND, Calif., April 26, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2010 financial results on Monday, May 3, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the p...
|
|
Sangamo BioSciences Appoints William R. Ringo as Chairman of the Board of Directors
Apr 19, 2010
|
10.1 KB |
|
| |
RICHMOND, Calif., April 19, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced the appointment of William R. Ringo to the position of chairman of the Company's boar...
|
|
Sangamo BioSciences Appoints Dr. Stephen G. Dilly to Its Board of Directors
Apr 1, 2010
|
9.6 KB |
|
| |
RICHMOND, Calif., April 1, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the appointment of Stephen G. Dilly, M.B.B.S., Ph.D., to the company's board of...
|
|
Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Mar 3, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., March 3, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 11:00 am ET on Wednesda...
|
|
Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
Feb 3, 2010
|
21.7 KB |
|
| |
RICHMOND, Calif., Feb 03, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2009 financial results and accomplishments and provided an outlook for 2010.
For the fourth quarter ended December 31, 2009, Sangamo reported a consolidated net loss of $2.4 million, or $0.05 ...
|
|
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Feb 1, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., Feb 01, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, F...
|
|
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Jan 27, 2010
|
7.6 KB |
|
| |
RICHMOND, Calif., Jan 27, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2009 financial results on Wednesday, February 3, 2010, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which...
|
|
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
Jan 19, 2010
|
12.1 KB |
|
| |
RICHMOND, Calif., Jan 19, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 201...
|
|
Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline
Jan 11, 2010
|
15.7 KB |
|
| |
RICHMOND, Calif., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Ju...
|
|
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Jan 6, 2010
|
7.1 KB |
|
| |
RICHMOND, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 2:30 pm PT (5:30 pm ET)...
|
|
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
Dec 9, 2009
|
14.9 KB |
|
| |
RICHMOND, Calif., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at th...
|
|
|
